{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:28:57Z","timestamp":1767677337336},"reference-count":0,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2000,1,1]],"date-time":"2000-01-01T00:00:00Z","timestamp":946684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Infectious Diseases and Medical Microbiology"],"published-print":{"date-parts":[[2001,1]]},"abstract":"<jats:p>Knowledge pertaining to hepatitis C virus (HCV)\/human immunodeficiency virus (HIV) co\u2010infection is currently incomplete or conflicting. Several points are well studied, however. Plasma HCV RNA levels are higher in matched HIV\u2010infected people than in HIV\u2010seronegative control subjects and are inversely correlated with CD4<jats:sup>+<\/jats:sup> T lymphocyte counts. HCV genotype does not appear to influence this value. Co\u2010infected individuals develop histological and clinical features of HCV liver disease more rapidly than HIV\u2010seronegative patients. Co\u2010infected individuals appear to respond to interferon\u2010alpha therapy equally as well as HIV\u2010seronegative HCV\u2010infected adults, but minimal information exists regarding the efficacy and toxicity of combination HCV therapy (interferon\u2010alpha plus ribavirin) in this population. Adverse consequences of highly active antiretroviral therapy in co\u2010infected patients include hepatic toxicity and, in a minority of patients, an \u2032immune restoration syndrome\u2032. It is unclear whether long term, highly active antiretroviral therapy positively or negatively influences the natural history of HCV infection.<\/jats:p>","DOI":"10.1155\/2001\/542056","type":"journal-article","created":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T07:59:08Z","timestamp":1458028748000},"page":"157-163","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characteristics of Hepatitis C Virus Infection in HIV\u2010Infected People"],"prefix":"10.1155","volume":"12","author":[{"given":"Curtis L","family":"Cooper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew D","family":"Badley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan B","family":"Angel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,6]]},"container-title":["Canadian Journal of Infectious Diseases and Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/cjidmm\/2001\/542056.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/2001\/542056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T09:26:13Z","timestamp":1722331573000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/2001\/542056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1]]},"references-count":0,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,1]]}},"alternative-id":["10.1155\/2001\/542056"],"URL":"https:\/\/doi.org\/10.1155\/2001\/542056","archive":["Portico"],"relation":{},"ISSN":["1712-9532","1918-1493"],"issn-type":[{"type":"print","value":"1712-9532"},{"type":"electronic","value":"1918-1493"}],"subject":[],"published":{"date-parts":[[2001,1]]},"assertion":[{"value":"2001-06-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}